Homepage Top Section2

Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three

As per terms of the deal, Immatics will secure an upfront payment of up to $50m from GSK for two initial programmes. Immatics has an option to secure

The approval from the European Commission (EC) makes VYNDAQEL the first and only treatment for patients with ATTR-CM in the European Union (EU). Considered to be a rare,

The company will invest around $109m to develop the 135,000ft² gene therapy manufacturing facility. North Carolina Governor Roy Cooper said: “With our powerhouse research centres and highly-skilled workforce,

Beovu is claimed to be the first EC-approved anti-VEGF treatment to show better resolution of retinal fluid (IRF/SRF) against aflibercept. Wet AMD, a chronic and degenerative eye disease,

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers

Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restricting its interactions with both PD-1 and

The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major

The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous